The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

THE MANAGEMENT of plaque psoriasis has evolved significantly over the past two decades, with biologic treatments becoming ...

A real-world study finds elderly psoriasis patients treated with IL-17 and IL-23 inhibitors achieve comparable long-term ...

The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.

Instead of just treating psoriasis, we may be directly treating ... Even for really good biologic agents to succeed, there are certain mindset-related obstacles that I anticipate many patients ...

WEDNESDAY, April 16, 2025 (HealthDay News) -- Patients with generalized pustular psoriasis (GPP ... alterations of off-label biologics and nonsteroidal systemic agents. "Treatment strategy ...